ArticleCancer immunology research2018
Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.
Article in Cancer immunology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
134 citing papers in PubMed, 2 syntheses or guidelines pooled it, 210 citations in OpenAlex.
- Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects.Frontiers in immunology · 2024Pooled it
- Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials.Frontiers in oncology · 2021Pooled it
- Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.Journal for immunotherapy of cancer · 2021Trial
- Radiotherapy induces responses of lung cancer to CTLA-4 blockade.Nature medicine · 2018Trial
- IL-2/CD25 acts within the tumor microenvironment to reprogram tumor-specific cytotoxic CD8Journal for immunotherapy of cancer · 2026Article
- Radiotherapy-Associated Systemic Antitumor Responses Beyond the Classical Abscopal Paradigm.Cancers · 2026Review
- Mechanisms and disease relevance of mitochondrial translation in humans.Nature reviews. Molecular cell biology · 2026Review
- Analysis of the TCRβ repertoire characteristics when combining radiotherapy and immunotherapy in cancer.Oncology letters · 2026Article
- Beyond local control: radiotherapy-immunotherapy combinations fromFrontiers in genetics · 2026Review
- Iodine-125 brachytherapy triggers immunogenic cell death and potentiates anti-PD-L1 immunotherapy in bone metastatic triple-negative breast cancer.Frontiers in immunology · 2026Article
- Combination LIGHT overexpression and checkpoint blockade disrupts the tumor immune environment impacting colorectal liver metastases.Science advances · 2025Article
- Prognostic value of tumor-infiltrating lymphocytes in irradiated node-positive breast cancer patients.Breast (Edinburgh, Scotland) · 2025Article
- DNA damage repair inhibitors boost targeted radionuclide therapy and immunotherapy of prostate cancer.Apoptosis : an international journal on programmed cell death · 2025Article
- The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy.Cancer immunology research · 2025Article
- T-Cell Receptor Repertoires Show Dynamic Variation Between Diagnosis and Relapse of Diffuse Large B-Cell Lymphoma.EJHaem · 2025Article
- The untapped potential of radiation and immunotherapy for hormone receptor-positive breast cancer.NPJ breast cancer · 2025Review
- Beyond the tumor microenvironment: Orchestrating systemic T‑cell response for next‑generation cancer immunotherapy (Review).International journal of oncology · 2025Review
- Dynamic Changes in Lymphocyte Subsets and Inflammation-Immune-Related Proteins in Patients with Thyroid Papillary Carcinoma before and after Radioactive Iodine Therapy.Journal of proteome research · 2025Article
- Rationally designed anti-autophagy nanosystems for reversing the immunosuppressive network in the tumor environment.Nanomedicine (London, England) · 2025Article
- Unveiling the immunological terrain of pancreatic ductal adenocarcinoma: strategies to prompt immunotherapy from Mendelian randomization.Discover oncology · 2025Article
74 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
Immune checkpoint inhibitors activate T cells to reject tumors. Unique tumor mutations are key T-cell targets, but a comprehensive understanding of the nature of a successful antitumor T-cell response is lacking. To investigate the T-cell receptor (TCR) repertoire associated with treatment success versus failure, we used a well-characterized mouse carcinoma that is rejected by CD8 T cells in mice treated with radiotherapy (RT) and anti-CTLA-4 in combination, but not as monotherapy, and comprehensively analyzed tumor-infiltrating lymphocytes (TILs) by high-throughput sequencing of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.